Smart ECM
Account
RESDotcom SrlEvento 491027 / Edizione 1

XIII Annual meeting on pituitary tumors uptodate on pitnet from basic research to clinical management

Convegno ECM residenziale su tumori ipofisari (PitNET): aggiornamenti su patologia molecolare, genetica, imaging, neurochirurgia, radioterapia e gestione di acromegalia e malattia di Cushing. Destinato a endocrinologi, neurochirurghi, radiologi e specialisti multidisciplinari.

Provider
Dotcom SrlDotcom Srl (680)
Crediti ECM
10
Costo
Gratuito
Durata
10 ore
Date
26 - 27 novembre 2026
Richiedi info iscrizione
Aggiungi al Piano

Razionale scientifico

Pituitary adenomas/PitNET represents a complex disease, with a wide spectrum of clinical manifestations, from small benign lesions to aggressive PitNET, according to the ability of secreting different hormones or pro-hormones or of invading the neighbouring anatomical structures and to treatment resistance. Macroadenomas can cause mass effect, consisting of visual field defects, headache or hypopituitarism. People with hypopituitarism due to pituitary adenomas have an approximately 2-fold increase in all-cause mortality compared with the general population. Some syndromes of pituitary hormone excess are also associated with excess all-cause mortality. Acromegaly was associated with a 2-fold increase in all-cause mortality rate in studies published before 2008, but not in more recently published studies or in the subgroups of patients who achieved biochemical control of the disease. Cushing disease has been associated with a 3-fold increase in all-cause mortality rate. Aggressive PitNETs (APTs) are a small subset, around 10% of all PitNETs, defined as tumours which are radiologically invasive with unusually rapid tumour growth or clinically relevant tumour growth despite optimal standard therapies. Pituitary carcinomas (PCs) specifically denote APTs that have metastasised (craniospinal or systemic) and comprise up to 0.4% of all PitNETs. Current guidelines for the management of APTs and PCs recommend treatment with surgery, radiotherapy and temozolomide; however by definition these tumours progress despite these therapies and treatment options beyond current recommendations are experimental. In this field, precision medicine management is a rapidly expanding area that enables delivery of molecular based personalised therapies, and this approach may improve outcomes for patients with PitNET. In the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments. The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between neuroendocrinologist, ophthalmologist, pathologists, neurosurgeons, radiotherapist and nuclear medicine physician. The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease - Faculty of Medicine, Universita' Cattolica del Sacro Cuore, Rome.

Luogo

Hotel Donna Camilla Savelli
Via Garibaldi 27, Roma (RM)

Programma

1st Day - Thursday, November 26th 2026
  • 13.00ROUND TABLE: Bone Session - Bone fragility in Pituitary DiseasesA. Spada, A. M. Naciu, J. Bemporad, S. Chiloiro, L. Di Filippo, S. Frara, E. Sbardella, F. Bioletto
  • 14.00Registrations
  • 14.30Introduction e Welcome SpeechL. De Marinis, A. Bianchi, A.D. Ferone, A. Lenzi, G. Reimondo, A. Sgambato, A. Spada, G. Fioroni, R. Baldelli
  • 15.00PRESIDENTIAL LECTURE: Update sulla consensus per la gestione multidisciplinare dell'acromegaliaA. Giustina
  • 15.30I SESSION: Controversies in pathology reporting of PitNETM. Gessi, L. Poliani
  • 16.10LECTURE: Integration of molecular profiling in the diagnosis and prognostic stratification of PitNETsF. Roncaroli
  • 16.30Radiomics in Pituitary Adenomas (PitNETs): From Imaging Biomarkers to Clinical TranslationM. Puig Domingo
  • 16.50Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumorsF. Gatto
  • 17.10Personalizing radiotherapy for PitNETs: indications, timing and modern techniquesA. Martino, G. Minniti
  • 17.40Discussion on the topics covered
  • 18.00PRESIDENTIAL LECTURE: Radiometabolic therapy in NET and PitNET: the Italian Experience 2026D. Ferone
  • 18.30Conclusions
2nd Day - Friday November 27th, 2026
  • 08.30Registration
  • 09.00PRESIDENTIAL LECTURE: A concept of Pituitary Tumours Centers of Excellence - PTCOEF. Casanueva
  • 09.30II SESSION: Genetic obesities, new treatments and real-world experienceP. Marzullo
  • 09.50Lights and Shadows of rhGH therapy in the adultV. Gasco, D. Cuboni
  • 10.10Long-acting growth hormone for pediatric GHD: state of the artM. Cappa
  • 10.30Coffee Break
  • 10.50III SESSION: The Genetic Landscape of GH Secreting PitNET: Current Evidences and future perspectivesG. L. Scaglione, G. Trivellin
  • 11.20Patient Perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society International patient SurveyN. Karavitaki
  • 11.40Surgical management of sellar and parasellar tumors: technical adjuncts and modern outcomesF. Doglietto
  • 12.00News in radiological techniques of aggressive Pituitary TumorsS. Gaudino
  • 12.20The contribution of Nuclear Medicine: when and why?C. Caldarella
  • 12.50Discussion on topics
  • 13.10Light Lunch
  • 14.00IV SESSION: Disease Burden in Cushing's Syndrome - mechanism and treatment strategiesA. Isidori
  • 14.20Peripheral blockers and central acting drugs in the treatment of Cushing's diseaseC. Simeoli
  • 14.40Combination therapy for Cushing's diseaseR. Pivonello
  • 15.00Real-life data on pasireotide in monotherapy or combined in active Cushing's diseaseM. Barbot
  • 15.20Discussion on topics
  • 15.40LECTURE: Biological and clinical implications of the tumor microenvironment in non-functioning PitNETsM.D. Ilie
  • 16.00Discussion on topics
  • 16.20Closing remarks - Verifica di apprendimento Ecm

Responsabili del corso

DOTCOM SRL

Provider

ID Provider: N° 680

Città: Roma (RM)

Tipologia: Società, Agenzie Ed Enti Privati

Stato accreditamento: Standard - 2° Rinnovo

  • Medico Chirurgo, Endocrinologia e malattie del ricambio Antonio Bianchi

    Responsabile scientifico

    Specializzazione: Patologie ipotalamo-ipofisarie

    Struttura: Fondazione Policlinico Universitario A. Gemelli - IRCCS Roma

    Ruolo: Dirigente medico I livello U.O.S. di Patologie Ipotalamo-ipofisarie

  • Medico Chirurgo, Endocrinologia e malattie del ricambio Laura De Marinis

    Responsabile scientifico

    Specializzazione: Patologie ipotalamo-ipofisarie

    Struttura: Universita' Cattolica del Sacro Cuore

    Ruolo: Coordinatore Scientifico Master Universitario II Livello in diagnosi e terapia delle patologie ipotalamo-ipofisarie

Relatori e docenti

  • Medico Chirurgo, Endocrinologia Gianluca Aimaretti

    Moderatore

    Specializzazione: Endocrinologia

    Struttura: Universita' del Piemonte Orientale

    Ruolo: Professore Ordinario di Endocrinologia

  • Medico Chirurgo, Endocrinologia Mattia Barbot

    Relatore

    Specializzazione: Endocrinologia

    Struttura: Universita' degli Studi di Padova

    Ruolo: Ricercatore strutturato

  • Medico Chirurgo, Medicina Nucleare Carmelo Caldarella

    Relatore

    Specializzazione: Medicina Nucleare

    Struttura: Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

    Ruolo: Dirigente Medico, Centro PET TC

  • Medico Chirurgo, Endocrinologia e malattie del ricambio Salvatore Cannavo

    Moderatore

    Specializzazione: Endocrinologia

    Struttura: Universita' degli Studi di Messina

    Ruolo: Professore Ordinario di Endocrinologia

  • Medico Chirurgo, Patologia Clinica Ettore Domenico Capoluongo

    Moderatore

    Specializzazione: Biochimica clinica e Biologia molecolare clinica

    Struttura: Universita' degli studi di Napoli Federico II

    Ruolo: Ordinario di Biochimica clinica e Biologia molecolare clinica

Domande frequenti

L'evento è accreditato per: Medico Chirurgo (Oftalmologia, Medicina Nucleare, Gastroenterologia, Neuroradiologia, Otorinolaringoiatria, Endocrinologia, Genetica Medica, Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia), Medicina Interna, Chirurgia Generale, Neurochirurgia, Radiodiagnostica, Malattie Metaboliche E Diabetologia, Radioterapia, Anatomia Patologica).

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci